Premium
AUD researcher and pharma CEO develops new medication
Author(s) -
Knopf Alison
Publication year - 2019
Publication title -
alcoholism and drug abuse weekly
Language(s) - English
Resource type - Journals
eISSN - 1556-7591
pISSN - 1042-1394
DOI - 10.1002/adaw.32305
Subject(s) - ondansetron , medicine , addiction , psychiatry , family medicine , alternative medicine , traditional medicine , psychology , pathology
Bankole Johnson, D.Sc., M.D., is the chairman of Adial Pharmaceuticals, which is developing a medication—AD04, a very low‐dose formulation of ondansetron—for the treatment of alcohol use disorders (AUDs). Johnson has long studied medications – ondansetron in particular ‐‐ to treat AUDs (see ADAW , Oct. 15, 2007, Feb. 11, 2008, June 16, 2008, Nov. 3, 2008, June 7, 2010, August 16, 2010, Jan. 31, 2011, Feb. 24, 2014), and most recently has been named the 2019 recipient of the American Society of Addiction Medicine's (ASAM's) R. Brinkley Smithers Distinguished Scientist Award, which will be presented, along with the accompanying lecture, at ASAM's annual conference in Orlando next month.